| pubmed-article:17329575 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17329575 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:17329575 | lifeskim:mentions | umls-concept:C0011854 | lld:lifeskim |
| pubmed-article:17329575 | lifeskim:mentions | umls-concept:C0232804 | lld:lifeskim |
| pubmed-article:17329575 | lifeskim:mentions | umls-concept:C0730345 | lld:lifeskim |
| pubmed-article:17329575 | lifeskim:mentions | umls-concept:C0205329 | lld:lifeskim |
| pubmed-article:17329575 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17329575 | pubmed:dateCreated | 2007-3-28 | lld:pubmed |
| pubmed-article:17329575 | pubmed:abstractText | This study aimed to establish the time of initiation and the determinants of renal function decline in type 1 diabetes. Until now, such decline has been assumed to be a late-occurring event associated with proteinuria. A total of 267 patients with normoalbuminuria and 301 patients with microalbuminuria were followed for 8 to 12 yr. Linear trends (slopes) in GFR were estimated by serial measurement of serum cystatin C. Cases of early renal function decline were defined by loss in cystatin C GFR that exceeded -3.3%/yr, a threshold that corresponds to the 2.5th percentile of the distribution of GFR slopes in an independent nondiabetic normotensive population. Cases of early renal function decline occurred in 9% (mean slope -4.4; range -5.9 to -3.3%/yr) of the normoalbuminuria group and 31% (mean slope -7.1; range -23.8 to -3.3%/yr) of the microalbuminuria group (P < 0.001). Risk for early renal function decline depended on whether microalbuminuria regressed, remained stable, or progressed, rising from 16 to 32 and 68%, respectively (P < 0.001). In multivariate analysis, risk for decline was higher after age 35 yr or when glycosylated hemoglobin exceeded 9% but did not vary with diabetes duration, smoking, BP, or angiotensin-converting enzyme inhibitor treatment. Contrary to the existing paradigm of diabetic nephropathy, progressive renal function decline in type 1 diabetes is an early event that occurs in a large proportion of patients with microalbuminuria. Together with testing for microalbuminuria, clinical protocols using cystatin C to diagnose early renal function decline and track response to therapeutic interventions should be developed. | lld:pubmed |
| pubmed-article:17329575 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17329575 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17329575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17329575 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17329575 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:17329575 | pubmed:issn | 1046-6673 | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:WarramJames... | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:KrolewskiAndr... | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:PerkinsBruce... | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:WeinbergJanic... | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:FicocielloLin... | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:SilvaKristen... | lld:pubmed |
| pubmed-article:17329575 | pubmed:author | pubmed-author:OstranderBets... | lld:pubmed |
| pubmed-article:17329575 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17329575 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:17329575 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17329575 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17329575 | pubmed:pagination | 1353-61 | lld:pubmed |
| pubmed-article:17329575 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:meshHeading | pubmed-meshheading:17329575... | lld:pubmed |
| pubmed-article:17329575 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17329575 | pubmed:articleTitle | Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. | lld:pubmed |
| pubmed-article:17329575 | pubmed:affiliation | Section on Genetics and Epidemiology, Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA. | lld:pubmed |
| pubmed-article:17329575 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17329575 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17329575 | lld:pubmed |
